The surprising part is that Gilead's shares slumped last month despite the late-stage success of its next major HIV single-tablet drug regimen: a fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide indicated for the …
Owning a stock that doubles in value in less than 11 months is exciting. But what word do you use for a stock that rises to 4.5 times its original price in that amount of time? Thrilling? Exhilarating? Whatever word is the best fit, it applies to …
On June 29th, 2017, research firm Jefferies upgraded the Company's stock rating from 'Hold' to 'Buy'. Sign up for your …
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no discrimination for whether it's good or …
Yahoo!6mon